Intergy Private Wealth LLC Makes New $321,000 Investment in Merck & Co., Inc. (NYSE:MRK)

Posted by Defense World Staff on Mar 27th, 2023

Intergy Private Wealth LLC bought a new position in Merck & Co., Inc. (NYSE:MRK – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,891 shares of the company’s stock, valued at approximately $321,000.

Several other large investors have also bought and sold shares of the company. Retirement Financial Solutions LLC purchased a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Legend Financial Advisors Inc. bought a new position in shares of Merck & Co., Inc. in the third quarter worth approximately $27,000. EdgeRock Capital LLC bought a new position in shares of Merck & Co., Inc. during the third quarter worth $30,000. Mach 1 Financial Group LLC bought a new position in shares of Merck & Co., Inc. during the third quarter worth $30,000. Finally, New Millennium Group LLC bought a new position in shares of Merck & Co., Inc. during the second quarter worth $35,000. 72.89% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Up 0.5 %

Shares of MRK opened at $104.80 on Monday. The firm has a market cap of $266.04 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 1.92 and a beta of 0.34. Merck & Co., Inc. has a 12-month low of $80.45 and a 12-month high of $115.49. The company’s 50-day moving average price is $107.56 and its 200 day moving average price is $103.02. The company has a current ratio of 1.47, a quick ratio of 1.23 and a debt-to-equity ratio of 0.62.

Merck & Co., Inc. (NYSE:MRK – Get Rating) last issued its quarterly earnings data on Thursday, February 2nd. The company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.56 by $0.06. The firm had revenue of $13.83 billion for the quarter, compared to analyst estimates of $13.66 billion. Merck & Co., Inc. had a net margin of 24.49% and a return on equity of 43.47%. Merck & Co., Inc.’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.80 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 6.87 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 10th. Investors of record on Wednesday, March 15th will be issued a $0.73 dividend. The ex-dividend date is Tuesday, March 14th. This represents a $2.92 annualized dividend and a yield of 2.79%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 51.14%.

Insider Activity at Merck & Co., Inc.

In related news, EVP Steven Mizell sold 1,815 shares of the business’s stock in a transaction dated Monday, February 13th. The shares were sold at an average price of $109.10, for a total value of $198,016.50. Following the sale, the executive vice president now directly owns 33,085 shares in the company, valued at approximately $3,609,573.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Merck & Co., Inc. news, EVP Steven Mizell sold 1,815 shares of the business’s stock in a transaction dated Monday, February 13th. The shares were sold at an average price of $109.10, for a total transaction of $198,016.50. Following the sale, the executive vice president now directly owns 33,085 shares in the company, valued at $3,609,573.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sanat Chattopadhyay sold 83,994 shares of the business’s stock in a transaction dated Monday, January 9th. The stock was sold at an average price of $112.29, for a total transaction of $9,431,686.26. Following the sale, the insider now owns 29,500 shares in the company, valued at $3,312,555. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 100,245 shares of company stock worth $11,168,256. Company insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on MRK. Atlantic Securities increased their price objective on shares of Merck & Co., Inc. from $122.00 to $127.00 and gave the company an “overweight” rating in a research report on Tuesday, March 7th. Credit Suisse Group increased their target price on shares of Merck & Co., Inc. from $125.00 to $126.00 and gave the company an “outperform” rating in a research note on Tuesday, March 7th. Cowen increased their target price on shares of Merck & Co., Inc. from $108.00 to $120.00 in a research note on Tuesday, January 3rd. Barclays increased their target price on shares of Merck & Co., Inc. from $110.00 to $128.00 in a research note on Tuesday, December 20th. Finally, Truist Financial increased their target price on shares of Merck & Co., Inc. from $106.00 to $118.00 and gave the company a “buy” rating in a research note on Friday, February 3rd. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.35.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.